Eli Lilly and Company has raised concerns over the seizure of suspected counterfeit products bearing its brand name Mounjaro (tirzepatide) following an enforcement drive by the Haryana state drug regulator in Gurugram.

The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.

“We have been made aware of a recent development in relation to the seizure of a suspicious and counterfeit products that allegedly carry our product brand name Mounjaro (Tirzepatide). The said seizure resulted from an enforcement drive conducted in Gurugram by officials from the state drugs regulatory authority, Haryana," read the statement.

Lilly statement outlined that it takes patient safety extremely seriously and welcomes regulatory authority’s action against illicit medicines. "We are actively supporting the investigation and will continue to work with regulatory and law enforcement authorities worldwide to protect patients from the risks of counterfeit products."

"Stronger, coordinated enforcement must be sustained if we are to protect patients from unsafe fake medicines," the Lilly statement concluded.